Condition
Advanced Non-Small Cell Lung Carcinoma
Total Trials
3
Recruiting
0
Active
0
Completed
1
Success Rate
33.3%-53% vs avg
Key Insights
Highlights
Success Rate
33% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
Termination Rate
66.7%
2 terminated out of 3 trials
Success Rate
33.3%
-53.2% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results33% success
Data Visualizations
Phase Distribution
2Total
P 2 (2)
Trial Status
Terminated2
Completed1
Trial Success Rate
33.3%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT03430063Phase 2TerminatedPrimary
A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer
NCT02325349Phase 2Terminated
PET/CT Imaging of Angiogenesis in Lung or Head and Neck Cancers Prior or During Chemotherapy With Antiangiogenic Agents
NCT02171286Completed
The Oncopanel Pilot (TOP) Study
Showing all 3 trials